SCHEMBL4667452

SCHEMBL4667452

CN1CCN(CCCn2cc(-c3cc(Nc4ccc(N(OC=O)S(=O)(=O)c5ccc(F)cc5F)cc4)ncn3)c3ccccc32)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCB P05771 3/20 0.40
PRKCA P17252 3/20 0.40
HTR6 P50406 3/20 0.40
KDR P35968 2/20 0.37
FLT1 P17948 1/20 0.37
FLT4 P35916 1/20 0.37
IGF1R P08069 1/20 0.36
CDK2 P24941 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
GSK3B P49841 3/20 0.35
CYP1A2 P05177 2/20 0.34
CYP2D6 P10635 2/20 0.34
CYP2C19 P33261 2/20 0.34
AXL P30530 1/20 0.34
USP2 O75604 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
ALOX15 P16050 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4666099 0.94 PRKCB (0.41) PRKCBPRKCAHTR6KDRFLT1
SCHEMBL4665992 0.89 CYP1A2 (0.35) PRKCAHTR6CYP1A2CYP2D6CYP2C19
SCHEMBL4665742 0.87 PRKCB (0.40) PRKCBPRKCAHTR6KDRFLT1
Formic Acid SCHEMBL4667447 0.86 PRKCB (0.42) PRKCBPRKCAHTR6KDRFLT1
SCHEMBL4663841 0.83 CYP3A4 (0.36) HTR6KDRFLT4CYP1A2CYP2D6
SCHEMBL4667477 0.82 EGFR (0.35) PRKCBPRKCACYP1A2CYP2D6CYP2C19
SCHEMBL4664247 0.82 CXCR1 (0.42) CYP1A2CYP2D6CYP2C19AXLUSP2
SCHEMBL4667432 0.80 CYP3A4 (0.42) CDK2CYP1A2CYP2D6CYP2C19USP2
Formic Acid SCHEMBL4666097 0.80 PRKCB (0.43) PRKCBPRKCAHTR6KDRFLT1
SCHEMBL4667488 0.80 EGFR (0.37) HTR6CYP1A2CYP2D6CYP2C19AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 PRKCB 337/4885PRKCA 349/4885HTR6 826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.